Cargando…

Patient-Reported Testing Burden of Breast Magnetic Resonance Imaging Among Women With Ductal Carcinoma In Situ: An Ancillary Study of the ECOG-ACRIN Cancer Research Group (E4112)

IMPORTANCE: The use of magnetic resonance imaging (MRI) in pretreatment planning of ductal carcinoma in situ (DCIS) remains controversial. Understanding changes in short-term health-related quality of life associated with breast MRI would allow for a more complete comparative effectiveness assessmen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fazeli, Soudabeh, Snyder, Bradley S., Gareen, Ilana F., Lehman, Constance D., Khan, Seema A., Romanoff, Justin, Gatsonis, Constantine A., Miller, Kathy D., Sparano, Joseph A., Comstock, Christopher E., Wagner, Lynne I., Carlos, Ruth C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2021
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8564581/ https://www.ncbi.nlm.nih.gov/pubmed/34726748 http://dx.doi.org/10.1001/jamanetworkopen.2021.29697

Ejemplares similares

Association Between Surgery Preference and Receipt in Ductal Carcinoma In Situ After Breast Magnetic Resonance Imaging: An Ancillary Study of the ECOG-ACRIN Cancer Research Group (E4112)
por: Fazeli, Soudabeh, et al.
Publicado: (2022)

Patient willingness for repeat screening and preference for CT colonography and optical colonoscopy in ACRIN 6664: the National CT Colonography trial
por: Gareen, Ilana F, et al.
Publicado: (2015)

A randomized study of genetic education versus usual care in tumor profiling for advanced cancer in the ECOG‐ACRIN Cancer Research Group (EAQ152)
por: Bradbury, Angela R., et al.
Publicado: (2021)

ECOG-ACRIN 2399: analysis of patient related outcomes after Chemoradiation for locally advanced head and neck Cancer
por: Cmelak, Anthony, et al.
Publicado: (2020)

Refined estimates of local recurrence risks by DCIS score adjusting for clinicopathological features: a combined analysis of ECOG-ACRIN E5194 and Ontario DCIS cohort studies
por: Rakovitch, E., et al.
Publicado: (2018)

Impact of African ancestry on the relationship between body mass index and survival in an early‐stage breast cancer trial (ECOG‐ACRIN E5103)
por: Ballinger, Tarah J., et al.
Publicado: (2022)

CNS involvement in AML at diagnosis is rare and does not affect response or survival: data from 11 ECOG-ACRIN trials
por: Ganzel, Chezi, et al.
Publicado: (2021)

Adherence to oral therapies among patients with renal cell carcinoma: Post hoc analysis of the ECOG‐ACRIN E2805 trial
por: Murphy, Caitlin C., et al.
Publicado: (2021)

Paclitaxel With or Without Cixutumumab as Second-Line Treatment of Metastatic Esophageal or Gastroesophageal Junction Cancer: A Randomized Phase II ECOG-ACRIN Trial
por: Stockton, Shannon, et al.
Publicado: (2023)

Impact of lung cancer screening results on participant health-related quality of life and state anxiety in the National Lung Screening Trial
por: Gareen, Ilana F, et al.
Publicado: (2014)

Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis
por: Tarhini, Ahmad A, et al.
Publicado: (2021)

Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial—ECOG-ACRIN EA6134
por: Atkins, Michael B., et al.
Publicado: (2023)

MicroRNA expression profiling predicts clinical outcome of carboplatin/paclitaxel-based therapy in metastatic melanoma treated on the ECOG-ACRIN trial E2603
por: Villaruz, Liza C., et al.
Publicado: (2015)

Phase II Trial of Eribulin in Patients With Metastatic Hormone Refractory Prostate Cancer: A Trial of the ECOG-ACRIN Cancer Research Group (E5805)
por: Stein, Mark N., et al.
Publicado: (2019)

Pilot trial of paclitaxel-trastuzumab adjuvant therapy for early stage breast cancer: a trial of the ECOG-ACRIN cancer research group (E2198)
por: Schneider, Bryan P, et al.
Publicado: (2015)

Rapid, real time pathology review for ECOG/ACRIN 1412: a novel and successful paradigm for future lymphoma clinical trials in the precision medicine era
por: King, Rebecca L., et al.
Publicado: (2018)

Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100
por: Schneider, B P, et al.
Publicado: (2014)

Trametinib in Patients With NF1-, GNAQ-, or GNA11-Mutant Tumors: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols S1 and S2
por: Wisinski, Kari B., et al.
Publicado: (2023)

Validation of brief symptom indexes among patients with recurrent or metastatic squamous cell carcinoma of the head and neck: A trial of the ECOG‐ACRIN Cancer Research Group (E1302)
por: Oswald, Laura B., et al.
Publicado: (2020)

Integrative analysis identifies an older female-linked AML patient group with better risk in ECOG-ACRIN Cancer Research Group’s clinical trial E3999
por: Rapaport, Franck, et al.
Publicado: (2022)

Phase III Prospectively Randomized Trial of Perioperative 5-FU After Curative Resection for Colon Cancer: An Intergroup Trial of the ECOG-ACRIN Cancer Research Group (E1292)
por: Kemeny, M. Margaret, et al.
Publicado: (2022)

Impact of Alternate b-Value Combinations and Metrics on the Predictive Performance and Repeatability of Diffusion-Weighted MRI in Breast Cancer Treatment: Results from the ECOG-ACRIN A6698 Trial
por: Partridge, Savannah C., et al.
Publicado: (2022)

Correction: Integrative analysis identifies an older female-linked AML patient group with better risk in ECOG-ACRIN Cancer Research Group’s clinical trial E3999
por: Rapaport, Franck, et al.
Publicado: (2023)

Bevacizumab’s Association With a Decreased Risk of Brain Metastases in ECOG-ACRIN E1505, a Phase 3 Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab in Surgically Resected NSCLC
por: Varlotto, John M., et al.
Publicado: (2022)

Racial and Ethnic Differences in Amyloid PET Positivity in Individuals With Mild Cognitive Impairment or Dementia: A Secondary Analysis of the Imaging Dementia–Evidence for Amyloid Scanning (IDEAS) Cohort Study
por: Wilkins, Consuelo H., et al.
Publicado: (2022)

Phase II Study of Palbociclib (PD-0332991) in CCND1, 2, or 3 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B
por: Clark, Amy S., et al.
Publicado: (2023)

Patient‐reported tolerability of veliparib combined with cisplatin and etoposide for treatment of extensive stage small cell lung cancer: Neurotoxicity and adherence data from the ECOG ACRIN cancer research group E2511 phase II randomized trial
por: Steffen McLouth, Laurie E., et al.
Publicado: (2020)

Species Differences in Stereoselective Pharmacokinetics of HSG4112, A New Anti-Obesity Agent
por: Bae, In Yong, et al.
Publicado: (2020)

Phase II study of rituximab given in conjunction with standard chemotherapy in primary central nervous system lymphoma (PCNSL): a trial of the ECOG-ACRIN cancer research group (E1F05)
por: Swinnen, Lode J., et al.
Publicado: (2017)

Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412
por: Nowakowski, Grzegorz S., et al.
Publicado: (2021)

S115: CONSOLIDATION WITH BLINATUMOMAB IMPROVES OVERALL AND RELAPSE-FREE SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: IMPACT OF AGE AND MRD LEVEL IN ECOG-ACRIN E1910
por: Litzow, Mark, et al.
Publicado: (2023)

Rev-erbα Inhibits Proliferation and Promotes Apoptosis of Preadipocytes through the Agonist GSK4112
por: Chu, Guiyan, et al.
Publicado: (2019)

Discovery and preclinical efficacy of HSG4112, a synthetic structural analog of glabridin, for the treatment of obesity
por: Choi, Leo Sungwong, et al.
Publicado: (2020)

REV-ERBα Agonist GSK4112 attenuates Fas-induced Acute Hepatic Damage in Mice
por: Shao, Ruyue, et al.
Publicado: (2021)

Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second- or third-line treatment of patients with EGFR wild-type advanced non-small cell lung cancer (ECOG-ACRIN 1512): a phase 2 randomised controlled trial
por: Neal, Joel W., et al.
Publicado: (2016)

Outcome with lenalidomide plus dexamethasone followed by early autologous stem cell transplantation in patients with newly diagnosed multiple myeloma on the ECOG-ACRIN E4A03 randomized clinical trial: long-term follow-up
por: Biran, N, et al.
Publicado: (2016)

Granulomatous and Sarcoid-like Immune-Related Adverse Events following CTLA4 and PD1 Blockade Adjuvant Therapy of Melanoma: A Combined Analysis of ECOG-ACRIN E1609 and SWOG S1404 Phase III Trials and a Literature Review
por: Eljilany, Islam, et al.
Publicado: (2023)

T100: Long term Follow-up of a Phase I Study Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A trial of the ECOG-ACRIN Research Group (E4412: Arms A-I)
por: Diefenbach, Catherine, et al.
Publicado: (2022)

Ancillary mathematics
por: Massey, Harrie Stewart Wilson, et al.
Publicado: (1959)

Arterial Properties as Determinants of Left Ventricular Mass and Fibrosis in Severe Aortic Stenosis: Findings From ACRIN PA 4008
por: Chirinos, Julio A., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_je0i1l4oehogv7sq614tirn130